X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
ZP4207 (dasiglucagon) is a glucagon receptor agonist, peptide drug candidate, which is currently being evaluated for the treatment of congenital hyperinsulinism.
Lead Product(s): Dasiglucagon
Therapeutic Area: Genetic Disease Product Name: ZP4207
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Details:
ZP4207 (dasiglucagon) is being investigated by Zealand Pharma for subcutaneous continuous infusion using a wearable pump system as a potential treatment of congenital hyperinsulinism in pediatric patients 7 days of age and older.
Lead Product(s): Dasiglucagon
Therapeutic Area: Genetic Disease Product Name: ZP4207
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2023
Details:
ZP4207 (dasiglucagon) subcutaneous injection is a glucagon receptor agonist and indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.
Lead Product(s): Dasiglucagon
Therapeutic Area: Genetic Disease Product Name: ZP4207
Highest Development Status: Phase II/ Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2023
Details:
Zegalogue (dasiglucagon) subcutaneous injection is a glucagon receptor agonist and indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.
Lead Product(s): Dasiglucagon
Therapeutic Area: Endocrinology Product Name: Zegalogue
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2023
Details:
The net proceeds will be used for supporting the late stage rare disease assets, including Zegalogue (dasiglucagon), a glucagon analog that acts to increase blood sugar levels, being developed for the treatment of congenital hyperinsulinism.
Lead Product(s): Dasiglucagon
Therapeutic Area: Genetic Disease Product Name: Zegalogue
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Danske Bank
Deal Size: $218.9 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 30, 2023
Details:
The net proceeds will be used for supporting the late stage rare disease assets, including Zegalogue (dasiglucagon), a glucagon analog that acts to increase blood sugar levels, being developed for the treatment of congenital hyperinsulinism.
Lead Product(s): Dasiglucagon
Therapeutic Area: Genetic Disease Product Name: Zegalogue
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Danske Bank A/S
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Private Placement March 30, 2023
Details:
Dasiglucagon (ZP4207) is a glucagon analog that is stable in aqueous solution and is thus suitable for administration via chronic subcutaneous infusion via pump.Phase 3 study demonstrates that dasiglucagon treatment resulted in a significant reduction in glucose infusion rate.
Lead Product(s): Dasiglucagon
Therapeutic Area: Genetic Disease Product Name: ZP4207
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2022
Details:
Under the terms of the agreement, Zealand will be responsible for certain planned development, regulatory, and manufacturing activities of Zegalogue (dasiglucagon) to support approval outside the U.S.
Lead Product(s): Dasiglucagon
Therapeutic Area: Endocrinology Product Name: Zegalogue
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: $39.2 million Upfront Cash: $3.4 million
Deal Type: Licensing Agreement September 07, 2022
Details:
The net proceeds from the Private Placement are expected to be used to strengthen Zealand’s ability to execute on the refocused strategy prioritizing R&D and entering partnerships for commercial and late-stage development products.
Lead Product(s): Dasiglucagon
Therapeutic Area: Endocrinology Product Name: ZP4207
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Danske Bank
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Private Placement June 01, 2022
Details:
ZP4207 (dasiglucagon) met the primary endpoint with statistical significance - reducing the requirement for intravenous glucose by 55% compared to placebo in this pediatric patient population (ages 7 days to 12 months) when compared to placebo.
Lead Product(s): Dasiglucagon
Therapeutic Area: Genetic Disease Product Name: ZP4207
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2022
Details:
Phase 3 trial, 17103 is designed to investigate the potential for chronic ZP4207 (dasiglucagon), a glucagon analog infusion delivered via a pump to prevent hypoglycemia in children with congenital hyperinsulinism in neonates upto 12 month old.
Lead Product(s): Dasiglucagon
Therapeutic Area: Genetic Disease Product Name: ZP4207
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2022
Details:
This new funding from Oberland Capital enables to continue robust clinical-stage pipeline, which includes multiple programs in Phase 3 trials across a range of metabolic and gastrointestinal diseases including ZP4207, as well as in pre-clinical pipeline.
Lead Product(s): Dasiglucagon
Therapeutic Area: Genetic Disease Product Name: ZP4207
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Oberland Capital Management
Deal Size: $200.0 million Upfront Cash: $100.0 million
Deal Type: Financing December 14, 2021
Details:
Under the terms of the agreement, DEKA and Zealand will develop a medical pump system that is suitable for use in combination with dasiglucagon. DEKA and its affiliates will be responsible for pump development and pump manufacturing activities.
Lead Product(s): Dasiglucagon
Therapeutic Area: Genetic Disease Product Name: ZP4207
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Zealand Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 05, 2021
Details:
ZEGALOGUE® (dasiglucagon) injection is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.
Lead Product(s): Dasiglucagon
Therapeutic Area: Endocrinology Product Name: Zegalogue
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2021
Details:
The approval was based on efficacy results from three randomized, double-blind, placebo-controlled multicenter Phase 3 studies of Zegalogue in children aged 6 to 17 and in adults with type 1 diabetes.
Lead Product(s): Dasiglucagon
Therapeutic Area: Endocrinology Product Name: Zegalogue
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2021
Details:
The primary endpoint of faster time to plasma glucose recovery was successfully reached, with a median time of 10 minutes achieved by those administered with Zegalogue, as opposed to 30-45 minutes for those on the placebo.
Lead Product(s): Dasiglucagon
Therapeutic Area: Endocrinology Product Name: Zegalogue
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2021
Details:
The dasiglucagon HypoPal® rescue pen is under FDA review as a potential fast and effective treatment of severe hypoglycemia in diabetes.
Lead Product(s): Dasiglucagon
Therapeutic Area: Endocrinology Product Name: HypoPal
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2020
Details:
The dasiglucagon HypoPal® rescue pen New Drug Application represents a major milestone in Zealand Pharma’s efforts to bring life changing therapies to people with diabetes.
Lead Product(s): Dasiglucagon
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2020
Details:
Single mini-doses of dasiglucagon effectively reduced time spent in hypoglycemia after meals in individuals who have undergone bariatric surgery.
Lead Product(s): Dasiglucagon
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
